|
1
|
Dennett C and Simon J: The role of
polycystic ovary syndrome in reproductive and metabolic health:
Overview and approaches for treatment. Diabetes Spectr. 28:116–120.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wolf W, Wattick RA, Kinkade ON and Olfert
MD: Geographical prevalence of polycystic ovary syndrome as
determined by region and race/ethnicity. Int J Environ Res Public
Health. 15(2589)2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Barthelmess E and Naz R: Polycystic ovary
syndrome: Current status and future perspective. Front Biosci
(Elite Ed). 6:104–119. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Talaei A, Adgi Z and Kelishadi M:
Idiopathic hirsutism and insulin resistance. Int J Endocrin.
2013(593197)2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rasquin Leon LI and Mayrin JV: Polycystic
ovarian disease. In: Stat Pearls [Internet]. Stat Pearls
Publishing, Treasure Island, FL, 2020.
|
|
6
|
Dumitrescu R, Mehedintu C, Briceag I,
Purcărea VL and Hudita D: Metformin-clinical pharmacology in PCOs.
J Med Life. 8:187–192. 2015.PubMed/NCBI
|
|
7
|
Açbay O and Gündoğdu S: Can metformin
reduce insulin resistance in polycystic ovary syndrome? Fertil
Steril. 65:946–949. 1996.PubMed/NCBI
|
|
8
|
Mellott EN, Sharon EM and Hensley TL:
Efficacy of metformin use to induce ovulation in women with
polycystic ovarian syndrome. Obstet Gynecol Int J. 9:465–469.
2018.
|
|
9
|
Lord J, Flight I and Norman R: Metformin
in polycystic ovary syndrome: Systematic review and meta-analysis.
BMJ. 25:951–953. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Foretz M, Guigas B and Viollet B:
Understanding the glucoregulatory mechanisms of metformin in type 2
diabetes mellitus. Nat Rev Endocrinol. 15:569–589. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Caudle KE, Gammal RS, Whirl-Carrillo M,
Hoffman JM, Relling MV and Klein TE: Evidence and resources to
implement pharmacogenetic knowledge for precision medicine. Am J
Health Syst Pharm. 73:1977–1985. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hatoum D and McGowan E: Recent advances in
the use of metformin: Can treating diabetes prevent breast cancer?
Biomed Res Int. 2015(548436)2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Guo Q, Liu Z, Jiang L, Liu M, Ma J, Yang
C, Han L, Nan K and Liang X: Metformin inhibits growth of human
non-small cell lung cancer cells via liver kinase B-1-independent
activation of adenosine monophosphate-activated protein kinase. Mol
Med Rep. 13:2590–2596. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Stein B, Calzolari D, Hellberg K, Hu YS,
He L, Hung CM, Toyama EQ, Ross DS, Lillemeier BF, Cantley LC, et
al: Quantitative in vivo proteomics of metformin response in liver
reveals AMPK-Dependent and -Independent signaling networks. Cell
Rep. 29:3331–3348.e7. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Goldenberg N and Glueck CJ: Is
pharmacogenomics our future? Metformin, ovulation and polymorphism
of the STK11 gene in polycystic ovary syndrome. Pharmacogenomics.
9:1163–1165. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Legro RS, Barnhart HX, Schlaff WD, Carr
BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern
PG, Cataldo NA, et al: Ovulatory response to treatment of
polycystic ovary syndrome is associated with a polymorphism in the
STK11 gene. J Clin Endocrinol Metab. 93:792–800. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rotterdam ESHRE/ASRM-Sponsored PCOS
consensus workshop group. Revised 2003 consensus on diagnostic
criteria and long-term health risks related to polycystic ovary
syndrome (PCOS). Hum Reprod. 19:41–47. 2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ferriman D and Gallwey JD: Clinical
assessment of body hair growth in women. J Clin Endocrinol Metab.
21:1440–1447. 1961.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bridger T, MacDonald S, Baltzer F and Rodd
C: Randomized placebo-controlled trial of metformin for adolescents
with polycystic ovary syndrome. Arch Pediatr Adolesc Med.
160:241–246. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang YW, He SJ, Feng X, Cheng J, Luo YT,
Tian L and Huang Q: Metformin: A review of its potential
indications. Drug Des Devel Ther. 11:2421–2429. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sam S and Ehrmann DA: Metformin therapy
for the reproductive and metabolic consequences of polycystic ovary
syndrome. Diabetologia. 60:1656–1661. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sharma S, Mathur DK, Paliwal V and
Bhargava P: Efficacy of metformin in the treatment of acne in women
with polycystic ovarian syndrome: A newer approach to acne therapy.
J Clin Aesthet Dermatol. 12:34–38. 2019.PubMed/NCBI
|
|
23
|
Yang PK, Hsu CY, Chen MJ, Lai MY, Li ZR,
Chen CH, Chen SU and Ho HN: The efficacy of 24-month metformin for
improving menses, hormones, and metabolic profiles in polycystic
ovary syndrome. J Clin Endocrinol Metab. 103:890–899.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Harborne L, Fleming R, Lyall H, Sattar N
and Norman J: Metformin or antiandrogen in the treatment of
hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab.
88:4116–4123. 2003.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kelly CJ and Gordon D: The effect of
metformin on hirsutism in polycystic ovary syndrome. Eur J
Endocrinol. 147:217–221. 2002.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Palomba S, Falbo A, Zullo F and Orio F Jr:
Evidence-Based and potential benefits of metformin in the
polycystic ovary syndrome: A comprehensive review. Endocr Rev.
30:1–50. 2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Li Q, Li C, Li H, Zeng L, Kang Z, Mao Y,
Tang X, Zheng P, He L, Luo F and Li Z: STK11 rs2075604 polymorphism
is associated with metformin efficacy in Chinese type 2 diabetes
mellitus. Int J Endocrinol. 2017(3402808)2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hussein MR, Ouda MH, Abdulwahid HH and Abo
Al-Maali HM: Association of genetic polymorphism of LKB/STK11 with
therapeutic response of metformin in women with polycystic ovary
syndrome. Eur J Mol Clin Med. 7:539–552. 2021.
|
|
29
|
Goodman NF, Cobin RH, Futterweit W, Glueck
JS, Legro RS and Carmina E: American Association of Clinical
Endocrinologists (AACE); American College of Endocrinology (ACE);
Androgen Excess and PCOS Society (AES). American Association of
ClinicaL Endocrinologists, American College of Endocrinology, and
Androgen Excess and PCOS Society Disease State ClinicaL Review:
Guide to the best practices in the evaluation and treatment of
polycystic ovary syndrome - part 1. Endocr Pract. 21:1291–300.
2015.PubMed/NCBI View Article : Google Scholar
|
